

118TH CONGRESS
1ST SESSION

H. R. 1375

To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.

IN THE HOUSE OF REPRESENTATIVES

MARCH 3, 2023

Mr. TRONE (for himself and Mr. MEUSER) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To allow the Secretary of Health and Human Services to deny approval of a new drug application for an opioid analgesic drug on the basis of such drug not being clinically superior to other commercially available drugs.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Ensuring the FDA
5 Fully Examines Clinical Trial Impact and Vitalness before
6 Endorsement Act” or the “EFFECTIVE Act”.

1 **SEC. 2. REQUIREMENT FOR APPROVAL OF NEW OPIOID AN-**
2 **ALGESICS.**

3 Section 505(c) of the Federal Food, Drug, and Cos-
4 metic Act (21 U.S.C. 355(c)) is amended by adding at
5 the end the following:

6 “(6) Notwithstanding any other provision of this sec-
7 tion, the Secretary may deny approval of an application
8 submitted under subsection (b) for an opioid analgesic
9 drug if the Secretary determines that such drug does not
10 provide a significant advantage, in terms of greater safety
11 or effectiveness, compared to an appropriate comparator
12 drug, as determined by the Secretary.”.

○